Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Daraprim

- PMLiVE

Lilly joins new Medicare scheme to reduce insulin prices

New model will cover seniors enrolled in Medicare Part D

- PMLiVE

FDA clears generic of Daraprim, the ‘poster drug’ for price-gouging

Drug hit headlines after price jumped from $13.50 to $750 overnight

- PMLiVE

US start-up EQRx promises approach that will slash drug prices

Plans to have its first drug on the market in just five years

- PMLiVE

GSK, Pfizer and Sanofi among drugmakers planning price hikes in US

Pricing pressures increase amid intense political scrutiny

- PMLiVE

Trump administration advances drug importation plan

Proposal would allow states to import drugs from Canada

- PMLiVE

House Democrats finally pass landmark drug pricing bill

Proposed legislation met with harsh criticism from pharma industry

- PMLiVE

Democrats’ final pricing plan announced, 250 drugs targeted

Would allow US federal government to negotiate prices of key medicines

- PMLiVE

Democrats reveal pricing plan with 250-drug hit list

Listed drugs are costing Medicare the most each year

- PMLiVE

Post-Shkreli KaloBios pledges transparent pricing

Will seek input from “key stakeholders” and share reasoning behind pricing of drugs

- PMLiVE

KaloBios files for bankruptcy protection

San Francisco biopharma's shares imploded in the wake of Martin Shkreli's arrest

- PMLiVE

Shkreli fallout claims Turing jobs and KaloBios’ listing

Both firms continue to suffer with job cuts and de-listing from the Nasdaq

- PMLiVE

Update: Shkreli resigns as Turing CEO, ousted from KaloBios

Shares in KaloBios had been hit hard when news of his arrest broke

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links